Condition

Paraganglioma

ClinicalTrials.gov condition label

Clinical trials11
Recruiting5
Common interventions25
Lead sponsors shown8

Clinical trials

11 shown
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsNCT04119024 · 2025-10-07
RECRUITING
Institutional Registry of Rare DiseasesNCT06573723 · 2024-07-01
RECRUITING
Using the EHR to Advance Genomic Medicine Across a Diverse Health SystemNCT06377033 · 2024-06-10
RECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican PatientsNCT06523582 · 2022-08-03
RECRUITING
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaNCT03206060 · 2017-10-10
RECRUITING
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.NCT04276597 · 2020-03-04
WITHDRAWN
Dynamic Whole Body Positron Emission Tomography/Computed Tomography ImagingNCT04017104 · 2019-11-01
UNKNOWN
DOTATOC PET/CT for Imaging NET PatientsNCT03583528 · 2018-07-11
ACTIVE_NOT_RECRUITING
Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNCT02834013 · 2017-01-30
ACTIVE_NOT_RECRUITING
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaNCT01204476 · 2010-10-01
COMPLETED
Specificity of Elevated Plasma EM66 Levels in PheochromocytomaNCT01022515 · 2008-11-01
COMPLETED

Common interventions

18F-FDG PET/CTDIAGNOSTIC_TEST268Ga-DOTATOC PET/CTDIAGNOSTIC_TEST2Biospecimen CollectionPROCEDURE2Computed TomographyPROCEDURE2Magnetic Resonance ImagingPROCEDURE2177Lu-DOTATOCDRUG118F-DCFPyL PET/CTDIAGNOSTIC_TEST1Behavioral nudgeBEHAVIORAL1BiopsyPROCEDURE1CixutumumabBIOLOGICAL1CyclophosphamideDRUG1Echocardiography TestPROCEDURE1EverolimusDRUG1Fludarabine PhosphateDRUG1Fludeoxyglucose F-18OTHER1Ga-68-DOTATATEDRUG1IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM CellsBIOLOGICAL1IpilimumabBIOLOGICAL1Laboratory Biomarker AnalysisOTHER1Lu-177-DOTATATEDRUG1NivolumabBIOLOGICAL1Octreotide AcetateDRUG1Pharmacological StudyOTHER1plasma EM66 & CgA levels assessmentOTHER1Positron Emission TomographyPROCEDURE1

Trial status mix

RECRUITING5
ACTIVE_NOT_RECRUITING2
COMPLETED2
UNKNOWN1
WITHDRAWN1

Phase mix

PHASE23
NA2
PHASE12

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.